Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Prolaris prostate cancer prognostic test. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2016 Authors' conclusions The Prolaris test is to be used as a prognostic assay in prostate cancer patients with clinically localized prostate cancer to assess tumor aggressiveness and predict 10-year cancer-specific mortality risk. Indexing Status Subject indexing assigned by CRD MeSH Humans; Male; Prognosis; Prostatic Neoplasms Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000783 Date abstract record published 14/06/2016 |